Biolinerx Stock Technical Analysis
| BLRX Stock | USD 2.99 0.04 1.36% |
As of the 12th of February 2026, BioLineRx shows the Risk Adjusted Performance of (0.03), standard deviation of 3.05, and Mean Deviation of 2.46. BioLineRx technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
BioLineRx Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as BioLineRx, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to BioLineRxBioLineRx | Build AI portfolio with BioLineRx Stock |
BioLineRx Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 26.0 | Strong Buy | 2 | Odds |
Most BioLineRx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioLineRx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioLineRx, talking to its executives and customers, or listening to BioLineRx conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. Projected growth potential of BioLineRx fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive BioLineRx assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.00) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
Understanding BioLineRx requires distinguishing between market price and book value, where the latter reflects BioLineRx's accounting equity. The concept of intrinsic value - what BioLineRx's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push BioLineRx's price substantially above or below its fundamental value.
It's important to distinguish between BioLineRx's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioLineRx should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, BioLineRx's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
BioLineRx 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioLineRx's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioLineRx.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in BioLineRx on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding BioLineRx or generate 0.0% return on investment in BioLineRx over 90 days. BioLineRx is related to or competes with Tharimmune, GeoVax Labs, Apollomics, Adlai Nortye, Aditxt, Moleculin Biotech, and Ainos. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology More
BioLineRx Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioLineRx's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioLineRx upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 13.04 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 4.95 |
BioLineRx Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLineRx's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioLineRx's standard deviation. In reality, there are many statistical measures that can use BioLineRx historical prices to predict the future BioLineRx's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.18) |
BioLineRx February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 2.46 | |||
| Coefficient Of Variation | (2,211) | |||
| Standard Deviation | 3.05 | |||
| Variance | 9.28 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 13.04 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 4.95 | |||
| Skewness | 0.1414 | |||
| Kurtosis | (0.29) |
BioLineRx Backtested Returns
BioLineRx secures Sharpe Ratio (or Efficiency) of -0.0376, which signifies that the company had a -0.0376 % return per unit of risk over the last 3 months. BioLineRx exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioLineRx's Mean Deviation of 2.46, risk adjusted performance of (0.03), and Standard Deviation of 3.05 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.84, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioLineRx's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioLineRx is expected to be smaller as well. At this point, BioLineRx has a negative expected return of -0.11%. Please make sure to confirm BioLineRx's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioLineRx performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.53 |
Good reverse predictability
BioLineRx has good reverse predictability. Overlapping area represents the amount of predictability between BioLineRx time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioLineRx price movement. The serial correlation of -0.53 indicates that about 53.0% of current BioLineRx price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.53 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
BioLineRx technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
BioLineRx Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for BioLineRx across different markets.
About BioLineRx Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of BioLineRx on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of BioLineRx based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on BioLineRx price pattern first instead of the macroeconomic environment surrounding BioLineRx. By analyzing BioLineRx's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of BioLineRx's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to BioLineRx specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 48.72 | 56.03 | 56.41 | PTB Ratio | 1.59 | 1.43 | 1.81 |
BioLineRx February 12, 2026 Technical Indicators
Most technical analysis of BioLineRx help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for BioLineRx from various momentum indicators to cycle indicators. When you analyze BioLineRx charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 2.46 | |||
| Coefficient Of Variation | (2,211) | |||
| Standard Deviation | 3.05 | |||
| Variance | 9.28 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 13.04 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 4.95 | |||
| Skewness | 0.1414 | |||
| Kurtosis | (0.29) |
BioLineRx February 12, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as BioLineRx stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.01 | ||
| Daily Balance Of Power | 1.00 | ||
| Rate Of Daily Change | 1.01 | ||
| Day Median Price | 2.97 | ||
| Day Typical Price | 2.98 | ||
| Price Action Indicator | 0.04 | ||
| Market Facilitation Index | 0.04 |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.